Skip to main content

Adaptive Biotechnologies Corporation (ADPT)

NASDAQ: ADPT · IEX Real-Time Price · USD
33.65
+0.01 (0.03%)
After-hours:Oct 22, 2021 7:49 PM EDT
33.64
-0.28 (-0.83%)
At close: Oct 22, 4:00 PM
Market Cap4.74B
Revenue (ttm)133.43M
Net Income (ttm)-171.23M
Shares Out140.36M
EPS (ttm)-1.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume253,231
Open33.80
Previous Close33.92
Day's Range32.97 - 34.17
52-Week Range29.74 - 71.25
Beta0.30
AnalystsBuy
Price Target56.67 (+68.5%)
Est. Earnings DateNov 3, 2021

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease i...

IndustryLife Sciences Tools & Services
IPO DateJun 27, 2019
CEOChad Robins
Employees622
Stock ExchangeNASDAQ
Ticker SymbolADPT
Full Company Profile

Financial Performance

In 2020, ADPT's revenue was $98.38 million, an increase of 15.65% compared to the previous year's $85.07 million. Losses were -$146.23 million, 113.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 56.67, which is an increase of 68.46% from the latest price.

Price Target
$56.67
(68.46% upside)
Analyst Consensus: Buy

News

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021

SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

2 weeks ago - GlobeNewsWire

Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform...

Real-world data show T-Detect™ COVID can detect prior SARS-CoV-2 infection nearly 12 months after initial diagnosis in some patients

2 weeks ago - GlobeNewsWire

Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, No...

Combined ID-IGHV report at time of diagnosis conveniently provides additional prognostic information while also enabling future MRD monitoring in patients Combined ID-IGHV report at time of diagnosis co...

3 weeks ago - GlobeNewsWire

Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle

New Partnership with Youth Organization STEM Paths Innovation Network (SPIN) Seeds Next Generation of Local Biotech Talent New Partnership with Youth Organization STEM Paths Innovation Network (SPIN) Se...

1 month ago - GlobeNewsWire

Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021

Research demonstrates the ability of Adaptive's immune medicine platform to distinguish natural infection from vaccine response and the ability to detect prior infection nearly 12 months after initial d...

1 month ago - GlobeNewsWire

Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

1 month ago - GlobeNewsWire

3 Life Science Stocks Cathy Wood's Buying Hand Over Fist Right Now

ARK Invest made multiple purchases of these stocks last week.

Other symbols:PATH
2 months ago - The Motley Fool

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

SAN FRANCISCO and SEATTLE, Aug. 10, 2021 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, and Adaptive Biotechnologies Corp. (Nasdaq: ADPT), a biotechnology com...

2 months ago - PRNewsWire

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 18.60% and 20.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

Diagnostics industry expert to lead commercialization of marketed products and drive global commercial expansion Diagnostics industry expert to lead commercialization of marketed products and drive glob...

2 months ago - GlobeNewsWire

Earnings Preview: Adaptive Biotechnologies (ADPT) Q2 Earnings Expected to Decline

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Inflation Concerns Ruin First Week of Earnings Season

Inflation Concerns Ruin First Week of Earnings Season

3 months ago - Zacks Investment Research

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021

SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

3 months ago - GlobeNewsWire

This Explosive Biotech Is Taking On a Huge New Market

Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.

Other symbols:ARKGGHNTRA
3 months ago - The Motley Fool

Adaptive Biotechnologies (ADPT) Upgraded to Buy: Here's Why

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known S...

Adaptive's immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminished Adaptive...

4 months ago - GlobeNewsWire

Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for...

Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin's Lymphoma Studies demonstrate value of MRD in no...

4 months ago - GlobeNewsWire

Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences

SEATTLE, May 20, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system i...

5 months ago - GlobeNewsWire

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 29.27% and 34.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Adaptive Biotechnologies Reports First Quarter 2021 Financial Results

SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...

5 months ago - GlobeNewsWire

Earnings Outlook for Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ:ADPT) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.

5 months ago - Benzinga

Earnings Preview: Adaptive Biotechnologies (ADPT) Q1 Earnings Expected to Decline

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference

SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

5 months ago - GlobeNewsWire

Andreas Halvorsen Takes Stake in Mudrick Capital Acquisition Following Merger Announcement

Viking Global leader Andreas Holversen disclosed a stake in Mudrick Capital Acquistion Corp. II (NASDAQ:MUDS) earlier this month, seeing yet another value opportunity in special purpose acquisition comp...

6 months ago - GuruFocus

GenomeWeb Index Drops 3% for 2nd Consecutive Month

Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% inc...

Other symbols:BRNGNMKVIVO
6 months ago - GuruFocus